[A16-25] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
Last updated 01.08.2016
Commission awarded on 02.05.2016 by the Federal Joint Committee (G-BA).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.